Retatrutide (LY-3437943) is an experimental drug for obesity developed by the American pharmaceutical company Eli Lilly and Company. It is a triple glucagon hormone receptor agonist (GLP-1, GIP, and GCGR receptors).
Retatrutide (LY-3437943) is an experimental drug for obesity developed by the American pharmaceutical company Eli Lilly and Company. It is a triple glucagon hormone receptor agonist (GLP-1, GIP, and GCGR receptors).
== Clinical trials == Retatrutide has been studied in a phase 2 trial involving adults without diabetes but with obesity or preobesity (overweight). Retatrutide is also being evaluated in phase 3 clinical trials. A substudy in adults with type 2 diabetes reported differences in total body fat mass between study groups at 36 weeks.
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).